Jason Westin, MD, MS, FACP

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed axi-cel's safety profile and an important factor for improving access to CAR-T therapies.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed recent and ongoing studies that are upending the paradigm in LBCL care.

The director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed the implications of overall survival data that he presented at ASCO’s 2023 conference.

The director of Lymphoma Clinical Research at the University of Texas MD Anderson Cancer Center, discussed the future of DLBCL treatment.